Literature DB >> 28363153

Structure activity study of carbonic anhydrase IX: Selective inhibition with ureido-substituted benzenesulfonamides.

Mam Y Mboge1, Brian P Mahon1, Nicole Lamas1, Lillien Socorro1, Fabrizio Carta2, Claudiu T Supuran2, Susan C Frost1, Robert McKenna3.   

Abstract

Ureido-substituted benzenesulfonamides (USBs) show great promise as selective and potent inhibitors for human carbonic anhydrase hCA IX and XII, with one such compound (SLC-0111/U-F) currently in clinical trials (clinical trials.gov, NCT02215850). In this study, the crystal structures of both hCA II (off-target) and an hCA IX-mimic (target) in complex with selected USBs (U-CH3, U-F, and U-NO2), at resolutions of 1.9 Å or better, are presented, and demonstrate differences in the binding modes within the two isoforms. The presence of residue Phe 131 in hCA II causes steric hindrance (U-CH3, 1765 nM; U-F, 960 nM; U-NO2, 15 nM) whereas in hCA IX (U-CH3, 7 nM; U-F, 45 nM; U-NO2, 1 nM) and hCA XII (U-CH3, 6 nM; U-F, 4 nM; U-NO2, 6 nM), 131 is a Val and Ala, respectively, allows for more favorable binding. Our results provide insight into the mechanism of USB selective inhibition and useful information for structural design and drug development, including synthesis of hybrid USB compounds with improved physiochemical properties.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Benzenesulfonamides; Cancer therapy; Carbonic anhydrase IX; Structure-activity relationships; X-ray crystallography; hCA IX-Mimic

Mesh:

Substances:

Year:  2017        PMID: 28363153      PMCID: PMC5946058          DOI: 10.1016/j.ejmech.2017.03.026

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  52 in total

Review 1.  Carbonic anhydrases: novel therapeutic applications for inhibitors and activators.

Authors:  Claudiu T Supuran
Journal:  Nat Rev Drug Discov       Date:  2008-02       Impact factor: 84.694

2.  Hypoxia-inducible expression of tumor-associated carbonic anhydrases.

Authors:  C C Wykoff; N J Beasley; P H Watson; K J Turner; J Pastorek; A Sibtain; G D Wilson; H Turley; K L Talks; P H Maxwell; C W Pugh; P J Ratcliffe; A L Harris
Journal:  Cancer Res       Date:  2000-12-15       Impact factor: 12.701

3.  Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer.

Authors:  S Ivanov; S Y Liao; A Ivanova; A Danilkovitch-Miagkova; N Tarasova; G Weirich; M J Merrill; M A Proescholdt; E H Oldfield; J Lee; J Zavada; A Waheed; W Sly; M I Lerman; E J Stanbridge
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

4.  Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling.

Authors:  C C Wykoff; C W Pugh; P H Maxwell; A L Harris; P J Ratcliffe
Journal:  Oncogene       Date:  2000-12-14       Impact factor: 9.867

Review 5.  The biology of cancer: metabolic reprogramming fuels cell growth and proliferation.

Authors:  Ralph J DeBerardinis; Julian J Lum; Georgia Hatzivassiliou; Craig B Thompson
Journal:  Cell Metab       Date:  2008-01       Impact factor: 27.287

6.  Crystal structure of the catalytic domain of the tumor-associated human carbonic anhydrase IX.

Authors:  Vincenzo Alterio; Mika Hilvo; Anna Di Fiore; Claudiu T Supuran; Peiwen Pan; Seppo Parkkila; Andrea Scaloni; Jaromir Pastorek; Silvia Pastorekova; Carlo Pedone; Andrea Scozzafava; Simona Maria Monti; Giuseppina De Simone
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-14       Impact factor: 11.205

7.  Imaging the hypoxia surrogate marker CA IX requires expression and catalytic activity for binding fluorescent sulfonamide inhibitors.

Authors:  Ludwig Dubois; Kim Douma; Claudiu T Supuran; Roland K Chiu; Marc A M J van Zandvoort; Silvia Pastoreková; Andrea Scozzafava; Bradly G Wouters; Philippe Lambin
Journal:  Radiother Oncol       Date:  2007-05-14       Impact factor: 6.280

8.  Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation.

Authors:  J Saarnio; S Parkkila; A K Parkkila; K Haukipuro; S Pastoreková; J Pastorek; M I Kairaluoma; T J Karttunen
Journal:  Am J Pathol       Date:  1998-07       Impact factor: 4.307

9.  Expression of a novel carbonic anhydrase, CA XIII, in normal and neoplastic colorectal mucosa.

Authors:  Laura Kummola; Jonna M Hämäläinen; Jyrki Kivelä; Antti J Kivelä; Juha Saarnio; Tuomo Karttunen; Seppo Parkkila
Journal:  BMC Cancer       Date:  2005-04-18       Impact factor: 4.430

10.  Intermittent hypoxia selects for genotypes and phenotypes that increase survival, invasion, and therapy resistance.

Authors:  Daniel Verduzco; Mark Lloyd; Liping Xu; Arig Ibrahim-Hashim; Yoganand Balagurunathan; Robert A Gatenby; Robert J Gillies
Journal:  PLoS One       Date:  2015-03-26       Impact factor: 3.240

View more
  12 in total

1.  Carbonic anhydrase IX proteoglycan-like and intracellular domains mediate pulmonary microvascular endothelial cell repair and angiogenesis.

Authors:  Reece P Stevens; Mikhail F Alexeyev; Natalia Kozhukhar; Viktoria Pastukh; Sunita S Paudel; Jessica Bell; Dhananjay T Tambe; Troy Stevens; Ji Young Lee
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2022-06-07       Impact factor: 6.011

2.  Inhibitory activity against carbonic anhydrase IX and XII as a candidate selection criterion in the development of new anticancer agents.

Authors:  Mikhail Krasavin; Stanislav Kalinin; Tatiana Sharonova; Claudiu T Supuran
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

Review 3.  Biophysical, Biochemical, and Cell Based Approaches Used to Decipher the Role of Carbonic Anhydrases in Cancer and to Evaluate the Potency of Targeted Inhibitors.

Authors:  Mam Y Mboge; Anusha Kota; Robert McKenna; Susan C Frost
Journal:  Int J Med Chem       Date:  2018-07-16

4.  Design, synthesis, in vitro inhibition and toxicological evaluation of human carbonic anhydrases I, II and IX inhibitors in 5-nitroimidazole series.

Authors:  Ashok Aspatwar; Nanda Kumar Parvathaneni; Harlan Barker; Emilie Anduran; Claudiu T Supuran; Ludwig Dubois; Philippe Lambin; Seppo Parkkila; Jean-Yves Winum
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

Review 5.  Reconsidering anion inhibitors in the general context of drug design studies of modulators of activity of the classical enzyme carbonic anhydrase.

Authors:  Alessio Nocentini; Andrea Angeli; Fabrizio Carta; Jean-Yves Winum; Raivis Zalubovskis; Simone Carradori; Clemente Capasso; William A Donald; Claudiu T Supuran
Journal:  J Enzyme Inhib Med Chem       Date:  2021-12       Impact factor: 5.051

Review 6.  Experimental Carbonic Anhydrase Inhibitors for the Treatment of Hypoxic Tumors.

Authors:  Claudiu T Supuran
Journal:  J Exp Pharmacol       Date:  2020-12-15

7.  Selective inhibition of carbonic anhydrase IX over carbonic anhydrase XII in breast cancer cells using benzene sulfonamides: Disconnect between activity and growth inhibition.

Authors:  Mam Y Mboge; Zhijuan Chen; Alyssa Wolff; John V Mathias; Chingkuang Tu; Kevin D Brown; Murat Bozdag; Fabrizio Carta; Claudiu T Supuran; Robert McKenna; Susan C Frost
Journal:  PLoS One       Date:  2018-11-19       Impact factor: 3.240

Review 8.  Cancer Drug Development of Carbonic Anhydrase Inhibitors beyond the Active Site.

Authors:  Srishti Singh; Carrie L Lomelino; Mam Y Mboge; Susan C Frost; Robert McKenna
Journal:  Molecules       Date:  2018-04-30       Impact factor: 4.411

9.  Investigation of the protective effect of acetazolamide and SLC-0111 on carbon tetrachloride-induced toxicity in fruit fly.

Authors:  Eda Güneş; Hasan Aydin; Hatice Ferhan Nizamlioğlu
Journal:  Toxicol Rep       Date:  2021-06-16

10.  Identification of non-classical hCA XII inhibitors using combination of computational approaches for drug design and discovery.

Authors:  Mohammad M Al-Sanea; Garri Chilingaryan; Narek Abelyan; Grigor Arakelov; Harutyun Sahakyan; Vahram G Arakelov; Karen Nazaryan; Shaimaa Hussein; Gharam M Alazmi; Haifa E Alsharari; Waad M Al-Faraj; Faten S Alruwaili; Nouf Q Albilasi; Tahani S Alsharari; Abdulaziz A S Alsaleh; Turki M Alazmi; Atiah H Almalki; Nasser H Alotaibi; Mohamed A Abdelgawad
Journal:  Sci Rep       Date:  2021-07-30       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.